CHMP recommends refusal of market authorisation for emapalumab (Gamifant) for primary haemophagocytic lymphohistiocytosis (HLH) in children under 18 years of age

Emapalumab is a monoclonal antibody that binds to and neutralises interferon gamma. Although several patients responded to treatment, the results of the study were not considered sufficient to conclude that it was effective in the treatment of HLH.


European Medicines Agency